Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Medivation, Inc.
The European Medicines Agency has OKd nine new medicines for EU-wide approval, but recommended against renewing the conditional marketing authorization of two drugs.
The European Medicines Agency is set to decide whether to back EU marketing approval for eight new drugs.
A mix of mega-rounds and smaller seed financings show investment happening at both ends of the venture capital spectrum. In public company financings, Gilead prices $2bn note offering, Biogen secures $1.5bn for Reata deal, Inhibrx completes a $200m PIPE and the IPO market shows new signs of life.
Pfizer’s Talzenna is not cost effective enough to be used on the National Health Service for patients with HER2-negative advanced breast cancer with inherited BRCA mutations, according to draft guidance from England’s health technology assessment body NICE.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.